While all three treatment types increased the insulin: glucagon ratio in those with T2D by attenuating the exaggerated glucagon response to arginine, and by improving the blunted insulin response, individuals with T2D still displayed a reduced insulin: glucagon ratio compared to nondiabetic controls (21). The gene discussed is INS; the disease is type 2 diabetes mellitus.